Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how optimizing dosing intervals and carefully considering combination strategies for bispecific antibodies in relapsed/refractory multiple myeloma could enhance treatment efficacy while managing toxicities and improving patient quality of life.

Recent Videos
4 experts in this video
4 experts in this video
7 experts are featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Related Content